Back to Search Start Over

Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension.

Authors :
Cracowski JL
Baguet JP
Ormezzano O
Bessard J
Stanke-Labesque F
Bessard G
Mallion JM
Source :
Hypertension (Dallas, Tex. : 1979) [Hypertension] 2003 Feb; Vol. 41 (2), pp. 286-8.
Publication Year :
2003

Abstract

In contrast with the huge amount of experimental data available, only few and somewhat unconvincing clinical studies support the hypothesis that oxidative stress is involved in the early stages of essential hypertension in humans. Isoprostanes are chemically stable lipid peroxidation products of arachidonic acid, the quantification of which provides a novel approach to the assessment of oxidative stress in vivo. The main objective of this study was to quantify the urinary levels of 15-F(2t)-IsoP in the early stages of essential hypertension, using gas chromatography/mass spectrometry, by comparing 30 patients with never-treated mild-to-moderate hypertension with 30 gender- and age-paired healthy controls. Urinary 15-F(2t)-IsoP levels were not significantly different in hypertensive patients (69+/-36 pmol/mmol creatinine) compared with controls (75+/-34 pmol/mmol creatinine, 95% confidence intervals on differences: -23 to 13). No significant correlation was found between basal urinary 15-F(2t)-IsoP levels and age, low-density lipoprotein cholesterol, glucose, clinical pulse pressure, carotid intima-media thickness, left ventricular mass index, or aortic pulse wave velocity. In conclusion, this study shows that lipid peroxidation is not increased in never-treated mild-to-moderate hypertension. This suggests that oxidative stress is not implicated in the pathogenesis of human essential hypertension, at least in the early stages.

Details

Language :
English
ISSN :
1524-4563
Volume :
41
Issue :
2
Database :
MEDLINE
Journal :
Hypertension (Dallas, Tex. : 1979)
Publication Type :
Academic Journal
Accession number :
12574096
Full Text :
https://doi.org/10.1161/01.hyp.0000050963.16405.e6